[1] Hanahan D. Hallmarks of cancer: new dimensions[J]. Cancer Discovery, 2022, 12(1): 31-46.
[2] Chong S J F, Lu J, Valentin R, et al. BCL-2 dependence is a favorable predictive marker of response to therapy for chronic lymphocytic leukemia[J]. Molecular Cancer, 2025, 24(1): 62.
[3] He Y, Jiang S, Cui Y, et al. Induction of IFIT1/IFIT3 and inhibition of Bcl-2 orchestrate the treatment of myeloma and leukemia via pyroptosis[J]. Cancer Letters, 2024, 588: 216797.
[4] Marcucci G, Byrd J C, Dai G, et al. Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia[J]. Blood, 2003, 101(2): 425-432.
[5] Vogler M, Braun Y, Smith V M, et al. The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy[J]. Signal Transduction and Targeted Therapy, 2025, 10(1): 91.
[6] Moyer A, Tanaka K, Cheng E H. Apoptosis in cancer biology and therapy[J]. Annual Review of Pathology-Mechanisms of Disease, 2025, 20(1): 303-328.
[7] Bhola P D, Letai A. Mitochondria: judges and executioners of cell death sentences[J]. Molecular Cell, 2016, 61(5): 695-704.
[8] Lagadinou E D, Sach A, Callahan K, et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells[J]. Cell Stem Cell, 2013, 12(3): 329-341.
[9] Vogler M, Dinsdale D, Sun X M, et al. A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells[J]. Cell Death & Differentiation, 2008, 15(5): 820-830.
[10] Lock R, Carol H, Houghton P J, et al. Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program[J]. Pediatric Blood & Cancer, 2008, 50(6): 1181-1189.
[11] Roberts A W, Seymour J F, Brown J R, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease[J]. Journal of Clinical Oncology, 2012, 30(5): 488-496.
[12] Souers A J, Leverson J D, Boghaert E R, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets[J]. Nature Medicine, 2013, 19(2): 202-208.
[13] Vo T T, Ryan J, Carrasco R, et al. Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapy success in AML[J]. Cell, 2012, 151(2): 344-355.
[14] Pan R, Hogdal L J, Benito J M, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia[J]. Cancer Discovery, 2014, 4(3): 362-375.
[15] Guo Y, Xue H, Hu N, et al. Discovery of the clinical candidate sonrotoclax (BGB-11417), a highly potent and selective inhibitor for both WT and G101V mutant bcl-2[J]. Journal of Medicinal Chemistry, 2024, 67(10): 7836-7858.
[16] Ma M M, Zhang Z F, Tian C, et al. Sonrotoclax (BGB-11417) synergistically amplifies the radiotherapy-elicited anti-tumor immune response[J]. Cancer Letters, 2025, 625: 217759.
[17] Luedtke D A, Niu X J, Pan Y H, et al. Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells[J]. Signal Transduction and Targeted Therapy, 2017, 2: 17012.
[18] Fiskus W, Cai T Y, DiNardo C D, et al. Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells[J]. Blood Cancer Journal, 2019, 9(2): 4.
[19] Dolnikova A, Kazantsev D, Klanova M, et al. Blockage of BCL-XL overcomes venetoclax resistance across BCL2+ lymphoid malignancies irrespective of BIM status[J]. Blood Advances, 2024, 8(13): 3532-3543.
[20] Leverson J D, Phillips D C, Mitten M J, et al. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy[J]. Science Translational Medicine, 2015, 7(279): 279ra40.
[21] Wang L, Doherty G A, Judd A S, et al. Discovery of A-1331852, a first-in-class, potent, and orally-bioavailable BCL-XL inhibitor[J]. ACS Medicinal Chemistry Letters, 2020, 11(10): 1829-1836.
[22] Zhu Z C, Liu J W, Yang C, et al. XPO1 inhibitor KPT-330 synergizes with Bcl-xL inhibitor to induce cancer cell apoptosis by perturbing rRNA processing and Mcl-1 protein synthesis[J]. Cell Death & Disease, 2019, 10(6): 395.
[23] Lakhani N J, Rasco D, Wang H B, et al. First-in-human study with preclinical data of BCL-2/BCL-xL inhibitor pelcitoclax in locally advanced or metastatic solid tumors[J]. Clinical Cancer Research, 2024, 30(3): 506-521.
[24] Hu H X, Li C Y, Song Y D, et al. Albumin nanocomplex of BCL-2/xL inhibitor reduced platelet toxicity and improved anticancer efficacy in myeloproliferative neoplasm and lymphoma[J]. Biomaterials, 2025, 322: 123347.
[25] Anderson M A, Deng J, Seymour J F, et al. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism[J]. Blood, 2016, 127(25): 3215-3224.
[26] Roberts A W, Davids M S, Pagel J M, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia[J]. The New England Journal of Medicine, 2016, 374(4): 311-322.
[27] Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study[J]. The Lancet Oncology, 2016, 17(6): 768-778.
[28] Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: Results from the full population of a phase II pivotal trial[J]. Journal of Clinical Oncology, 2019, 36(19): 1973-1980.
[29] Konopleva M, Pollyea D A, Potluri J, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia[J]. Cancer Discovery, 2016, 6(10): 1106-1117.
[30] Garciaz S, Hospital M A, Collette Y, et al. Venetoclax Resistance in Acute Myeloid Leukemia[J]. Cancers, 2024, 16(6): 1091.
[31] Nwosu G O, Ross D M, Powell J A, et al. Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia[J]. Cell Death & Disease, 2024, 15: 413.
[32] Zhang Q, Riley-Gillis B, Han L N, et al. Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia[J]. Signal Transduction and Targeted Therapy, 2022, 7: 51.
[33] Allen B, Bottomly D, Köhnke T, et al. A CEBPB/IL-1β/TNF-α feedback loop drives drug resistance to venetoclax and MDM2 inhibitors in monocytic leukemia[J]. Blood, 2025, 145(21): 2488-2506.
[34] Bhatt S, Pioso M S, Olesinski E A, et al. Reduced mitochondrial apoptotic priming drives resistance to BH3 mimetics in acute myeloid leukemia[J]. Cancer Cell, 2020, 38(6): 872-890.
[35] Blombery P, Anderson M A, Gong J N, et al. Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia[J]. Cancer Discovery, 2019, 9(3): 342-353.
[36] Blombery P, Thompson E R, Nguyen T, et al. Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukaemia progression on venetoclax[J]. Blood, 2020, 135(10): 773-777.
[37] Chong S J F, Zhu F, Dashevsky O, et al. Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignancies[J]. The Journal of Clinical Investigation, 2023, 133(22): e170169.
[38] Thomalla D, Beckmann L, Grimm C, et al. Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies[J]. Blood, 2022, 140(20): 2113-2126.
[39] Luo M X, Tan T N, Trussart M, et al. Venetoclax dose escalation rapidly activates a BAFF/BCL-2 survival axis in chronic lymphocytic leukemia[J]. Blood, 2024, 144(26): 2748-2761.
[40] DiNardo C D, Jonas B A, Pullarkat V, et al. Azacitidine and Venetoclax in previously untreated acute myeloid leukemia[J]. The New England Journal of Medicine, 2020, 383(7): 617-629.
[41] Wei A H, Strickland S A, Hou J Z, et al. Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: Results from a phase Ib/II study[J]. Journal of Clinical Oncology, 2019, 37(15): 1277-1284.
[42] Ma S, Seymour J F, Brander D M, et al. Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited-duration therapy[J]. Blood, 2021, 138(10): 836-846.
[43] Kater A P, Levin M D, Dubois J, et al. Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): Primary analysis of an open-label, randomised, phase 2 trial[J]. The Lancet Oncology, 2022, 23(6): 818-828.
[44] Ye F H, Zhang W, Fan C Y, et al. Antileukemic effect of venetoclax and hypomethylating agents via caspase-3/GSDME-mediated pyroptosis[J]. Journal of Translational Medicine, 2023, 21(1): 606.
[45] Lee J B, Khan D H, Hurren R, et al. Venetoclax enhances T cell-mediated antileukemic activity by increasing ROS production[J]. Blood, 2021, 138(3): 234-245.
[46] DiNardo C D, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia[J]. Blood, 2019, 133(1): 7-17.
[47] Cheung L C, Aya-Bonilla C, Cruickshank M N, et al. Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy[J]. Leukemia, 2023, 37(1): 61-71.
[48] Niu X J, Zhao J Y, Ma J, et al. Binding of released BIM to mcl-1 is a mechanism of intrinsic resistance to ABT-199 which can be overcome by combination with daunorubicin or cytarabine in AML cells[J]. Clinical Cancer Research, 2016, 22(17): 4440-4451.
[49] Wei A H, Montesinos P, Ivanov V, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial[J]. Blood, 2020, 335(24): 2137-2145.
[50] Othman J, Tiong I S, O’nions J, et al. Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy[J]. Blood, 2024, 143(4): 336-341.
[51] Seymour J F, Ma S, Brander D M, et al. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study[J]. The Lancet Oncology, 2017, 18(2): 230-240.
[52] Al-Sawaf O, Zhang C, Tandon M, et al. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial[J]. The Lancet Oncology, 2020, 21(9): 1188-1200.
[53] Brown J R, Seymour J F, Jurczak W, et al. Fixed-duration acalabrutinib combinations in untreated chronic lymphocytic leukemia[J]. The New England Journal of Medicine, 2025, 392(8): 748-762.
[54] Stanchina M D, Montoya S, Danilov A V, et al. Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukemia[J]. Nature Reviews Clinical Oncology, 2024, 21(12): 867-887.
[55] Hillmen P, Rawstron A C, Brock K, et al. Ibrutinib plus venetoclax in relapsed/refractory chronic lymphocytic leukemia: the CLARITY study[J]. Journal of Clinical Oncology, 2019, 37(30): 2722-2729.
[56] Davids M S, Ryan C E, Lampson B L, et al. Phase II Study of acalabrutinib, venetoclax, and obinutuzumab in a treatment-naïve chronic lymphocytic leukemia population enriched for high-risk disease[J]. Journal of Clinical Oncology, 2025, 43(7): 788-799.
[57] Kumar S K, Harrison S J, Cavo M, et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed or refractory multiple myeloma (BELLINI): final overall survival results from a randomised, phase 3 study[J]. The Lancet Haematology, 2025, 12(8): e574-e587.
[58] Costa L J, Davies F E, Monohan G P, et al. Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma[J]. Blood Advances, 2021, 5(19): 3748-3759.
[59] Luskin M R, Shimony S, Keating J, et al. Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemia[J]. Blood Advances, 2025, 9(3): 617-626.
[60] DiNardo C D, Jen W Y, Takahashi K, et al. Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia[J]. Leukemia, 2025, 39(4): 854-863.
)
